Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.07
-8.3%
$0.09
$0.07
$0.34
$743K0.517,722 shs201 shs
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
$0.58
$0.22
$2.40
$997K0.658.25 million shs1.89 million shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$0.32
+68.4%
$0.46
$0.16
$2.31
$3.18M0.649.07 million shs730.10 million shs
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
$3.11
$2.80
$1.71
$8.60
$7.80M0.73936,446 shs26,115 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynatronics Co. stock logo
DYNT
Dynatronics
-8.26%-20.54%-13.69%-48.15%-78.06%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00%0.00%0.00%0.00%0.00%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
+1.47%-39.40%-37.46%-87.28%-88.31%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
+1.30%-6.89%+15.61%+6.14%-42.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.37 of 5 stars
3.34.00.00.02.60.00.6
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
2.2333 of 5 stars
3.52.00.00.03.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynatronics Co. stock logo
DYNT
Dynatronics
0.00
N/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
0.00
N/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.50
Moderate Buy$11.673,603.70% Upside
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
3.00
Buy$28.00800.32% Upside

Current Analyst Ratings Breakdown

Latest DYNT, SINT, NVIV, and PSTV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$9.00
6/5/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $20.50
5/30/2025
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $28.00
5/5/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/5/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/21/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $20.00
4/21/2025
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$70.00 ➝ $30.00
3/28/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/28/2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $5.50
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynatronics Co. stock logo
DYNT
Dynatronics
$33.60M0.02N/AN/A$0.57 per share0.12
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/A$6.48 per shareN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$5.82M0.92N/AN/A($1.52) per share-0.21
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
$2.89M2.70N/AN/A$2.90 per share1.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynatronics Co. stock logo
DYNT
Dynatronics
-$2.70M-$0.78N/AN/A-8.35%-41.81%-9.56%N/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
-$11.02M-$50.56N/AN/A-483.85%-203.66%-104.76%8/4/2025 (Estimated)

Latest DYNT, SINT, NVIV, and PSTV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million
5/15/2025Q1 2025
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
-$0.71-$1.29-$0.58-$1.29$0.73 million$0.37 million
3/27/2025Q4 2024
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynatronics Co. stock logo
DYNT
Dynatronics
0.25
1.21
0.60
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
N/A
14.30
14.30
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
1.03
1.03
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
N/A
3.44
3.25

Institutional Ownership

CompanyInstitutional Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
13.78%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
18.38%

Insider Ownership

CompanyInsider Ownership
Dynatronics Co. stock logo
DYNT
Dynatronics
7.98%
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
2.45%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.76%
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynatronics Co. stock logo
DYNT
Dynatronics
20010.62 million8.11 millionNot Optionable
InVivo Therapeutics Holdings Corp. stock logo
NVIV
InVivo Therapeutics
63.11 million3.03 millionNot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2017.00 million16.36 millionNot Optionable
Sintx Technologies, Inc. stock logo
SINT
Sintx Technologies
402.51 million2.51 millionNot Optionable

Recent News About These Companies

SiNtx Technologies Inc.
SiNtx Technologies Inc.
Sintx Technologies announces changes to board, Chairman Bal to retire
SINTX Technologies Announces Strategic Changes to Board of Directors
Maxim Group Reaffirms Their Hold Rating on Sintx Technologies (SINT)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynatronics stock logo

Dynatronics NASDAQ:DYNT

$0.07 -0.01 (-8.26%)
As of 06/24/2025 11:00 AM Eastern

Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

InVivo Therapeutics stock logo

InVivo Therapeutics NASDAQ:NVIV

InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.

Plus Therapeutics stock logo

Plus Therapeutics NASDAQ:PSTV

$0.32 +0.13 (+68.45%)
Closing price 04:00 PM Eastern
Extended Trading
$0.37 +0.05 (+16.83%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Sintx Technologies stock logo

Sintx Technologies NASDAQ:SINT

$3.11 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$3.14 +0.03 (+0.96%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.